Author

Hongzi Chen

Institution: VenatoRx Pharmaceuticals (United States)

Observed institutions: Tufts Medical Center, United States Food and Drug Administration, The University of Texas at San Antonio Health Science Center, University of Washington, GlaxoSmithKline (United States), VenatoRx Pharmaceuticals (United States)

ORCID: 0009-0002-1561-952X

Observed ORCID: 0009-0002-1561-952X

OpenAlex ID: A5027867701

Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

2002 · Steven M. Haffner, Andrew S. Greenberg, et al. · Circulation · 880

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection

2024 · Greg Moeck, Leanne B. Gasink, et al. · Antimicrobial Agents and Chemotherapy · 29

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

2006 · Dahong Yu, Susan J Murdoch, et al. · Diabetes and Vascular Disease Research · 22

Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus

2007 · Jean-Paul Albertini, Stephen O. McMorn, et al. · Atherosclerosis · 21

Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?

2003 · Barry J. Goldstein, Alexander R. Cobitz, et al. · Current Medical Research and Opinion · 11

Pharmacokinetics and safety of single and repeat doses of ceftibuten in healthy participants: a phase 1 dose escalation study

2025 · Mary Beth Dorr, Carlos Fernando de Oliveira, et al. · Antimicrobial Agents and Chemotherapy · 8

Safety and pharmacokinetics of single and multiple doses of ledaborbactam etzadroxil with or without ceftibuten in healthy volunteers

2025 · Carlos Fernando de Oliveira, Mary Beth Dorr, et al. · Antimicrobial Agents and Chemotherapy · 4

1124-192 Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy

2004 · John D Brunzell, Santica Marcovina, et al. · Journal of the American College of Cardiology · 4

2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study

2023 · Greg Moeck, Leanne Gasink, et al. · Open Forum Infectious Diseases · 3

Uniqueness of permuted treatment estimator distributions in the proportional hazards model

1999 · Hongzi Chen, Steven Piantadosi · Communication in Statistics- Theory and Methods

Works count: 10

Citation count: 982

H-index: 6

I10-index: 5